x

Search for a research project

* (*) mandatory field

Other search option(s)

111 Result(s)

Sort by

Funded by an IRDiRC member =

Research projects

BELGIUM

VLAAMS BRABANT
LEUVEN

CANADA

Alberta
EDMONTON

Funded by an IRDiRC memberMRI biomarkers in ALS
University of Alberta
Department of Medicine, Division of Neurology

CANADA

Alberta
EDMONTON

Funded by an IRDiRC memberPromoting protection of functionally intact motor units in amyotrophic lateral sclerosis (ALS).
University of Alberta
Faculty of Physical Education and Recreation

CANADA

Colombie-Britannique
VANCOUVER

CANADA

Ontario
OTTAWA

Funded by an IRDiRC memberLoss of VAPB Function in Amyotrophic Lateral Sclerosis-8 (ALS8)
Ottawa Hospital Research Institute
Neuroscience

CANADA

Ontario
TORONTO

Funded by an IRDiRC memberThe TAR DNA-Binding Protein (TDP-43) and Amyotrophic Lateral Sclerosis
University of Toronto
Centre for Research in Neurodegenerative Disease

CANADA

Ontario
WATERLOO

Funded by an IRDiRC memberFolding and aggregation of ALS-associated mutant superoxide dismutases
University of Waterloo
Department of Chemistry

CANADA

Québec
MONTRÉAL

Funded by an IRDiRC memberSynaptic targets for therapeutic protection of motor function in a genetic model of ALS
Centre Hospitalier de l'Université de Montréal
Centre of Excellence in Neuromics of Université de Montréal (CENUM)

CANADA

Québec
MONTRÉAL

Funded by an IRDiRC memberRegeneration of motor neurons controlling movement and respiration from embryonic stem cells
Montreal Neurological Institute and Hospital
McGill University

CANADA

Québec
MONTRÉAL

Funded by an IRDiRC memberRegulation of motor neuron identity and circuit development
Montreal Neurological Institute and Hospital
McGill University

FINLAND

Finland
HELSINKI

Funded by an IRDiRC memberCDNF and MANF in genetic models of ALS
Biocenter 1, University of Helsinki
Institute of Biotechnology

FRANCE

AUVERGNE-RHONE-ALPES
CLERMONT-FERRAND

Study of Mitochondrial Functions and Oxidative Stress in ALS Patients
CHU de Clermont-Ferrand - Hôpital d'Estaing
Service d'hépato-gastro-entérologie

FRANCE

AUVERGNE-RHONE-ALPES
GRENOBLE

First study in France searching a link between Amyotrophic Lateral Sclerosis (ALS) and beta-N-methylamino-L-alanine (BMAA) cyanotoxin
CHU de Grenoble site Nord - Hôpital Albert Michallon
Pôle de psychiatrie et neurologie

FRANCE

GRAND-EST
STRASBOURG

Involvement of metabolic dysfunctions in the pathogenesis of amyotrophic lateral sclerosis
Faculté de médecine de Strasbourg - Louis Pasteur
Laboratoire de signalisations moléculaires et neurodégénérescence

FRANCE

HAUTS-DE-FRANCE
LILLE

Potential role for nocturnal PtcCO2 monitoring in the close follow up of amyotrophic lateral sclerosis patients
CHRU de Lille - Hôpital Albert Calmette
Clinique de Pneumologie - Centre de compétences Maladies pulmonaires rares

FRANCE

ILE-DE-FRANCE
PARIS

Localisation and identification of causative genes for amyotrohic lateral sclerosis
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Excitabilité, synapse & pathologies associées

FRANCE

ILE-DE-FRANCE
PARIS

Study of the interactions between microglial cells, macrophages and neurons from three axes in an animal model of amyotrophic lateral sclerosis
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Equipe "Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives"

FRANCE

ILE-DE-FRANCE
PARIS

Involvement of metabolic dysfunctions in the pathogenesis of amyotrophic lateral sclerosis
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Département des Maladies du Système Nerveux

FRANCE

ILE-DE-FRANCE
PARIS

From Movement Preparation to Gait Execution in ALS: : Combined Neurophysiological and Neuroimaging Approaches - FR
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Groupement hospitalier universitaire Pitié-Salpétrière

FRANCE

ILE-DE-FRANCE
PARIS

Funded by an IRDiRC memberPredict to prevent frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Institut du Cerveau et de la Moëlle épinière - INSERM U1127

FRANCE

ILE-DE-FRANCE
PARIS

Funded by an IRDiRC memberRNA-ALS: Dysregulation of RNA in the pathogenesis of ALS - FR
Institut du Cerveau et de la Moelle épinière
Traitement de la sclérose latérale amyotrophique : de la génétique au poisson zèbre

FRANCE

NOUVELLE AQUITAINE
LIMOGES

Funded by an IRDiRC memberBMAALS: First study in France seraching a link between Amyotrophic Lateral Sclerosis and BMAA's cyanotoxin
Faculté de médecine de Limoges
Institut d'épidémiologie neurologique et de neurologie tropicale

FRANCE

OCCITANIE
MONTPELLIER

Funded by an IRDiRC memberFaSMALS : Common Pathogenic Pathways and Therapeutics for SMA and ALS motoneuron diseases - FR
CHRU de Montpellier - Hôpital Saint-Eloi
Institut des Neurosciences de Montpellier - INSERM U1051

FRANCE

OCCITANIE
MONTPELLIER

Funded by an IRDiRC memberFrom knowledge base of the pathogenic astrocyte-motoneuron communication in amyotrophic lateral sclerosis to therapeutic approaches
CHRU de Montpellier - Hôpital Saint-Eloi
Institut des Neurosciences de Montpellier - INSERM U1051

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

MITOTARGET: mitochondrial apoptotic pathways in neurodegenerative diseases and assessment of the effects of new small molecules (WP4)
Parc scientifique et technologiques de Luminy
Institut de Biologie du Développement de Marseille-Luminy

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

GERMANY

Baden-Württemberg
TÜBINGEN

Cell Biology of the FTD/ALS Associated Nuclear Splice Factor TDP-43
Hertie-Institut für klinische Hirnforschung (HIH)
Abteilung für Neurodegeneration - Funktionelle Neurogenetik

GERMANY

Baden-Württemberg
TÜBINGEN

MITOTARGET: in vivo evidence of mitochondrial-targeted therapeutics (WP5)
Institut für Medizinische Genetik und angewandte Genomik Tübingen
Institut für Medizinische Genetik und angewandte Genomik

GERMANY

Baden-Württemberg
ULM

Epidemiology of motoneuron diseases - A case-control study
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie

GERMANY

Hessen
FRANKFURT AM MAIN

MITOTARGET: Mitochondriale Membran-Eigenschaften im Prozess der Neurodegeneration und Untersuchung der Effekte von neuen kleinen Molekülen (WP2)
Johann Wolfgang Goethe-Universität Frankfurt
Pharmakologisches Institut für Naturwissenschaftler

GERMANY

Niedersachsen
GÖTTINGEN

GERMANY

Nordrhein-Westfalen
BONN

Role of PGC-1A in the evolution of amyotrophic lateral sclerosis and effects of its regulation
Universitätsklinikum Bonn
Klinik für Neurodegenerative Erkrankungen & Gerontopsychiatrie

GERMANY

Nordrhein-Westfalen
ESSEN

Nutrition and Quality of Life in Amyotrophic Lateral Sclerosis
Universitätsklinikum Essen
Klinik für Neurologie

GERMANY

Nordrhein-Westfalen
MÜNSTER

GERMANY

Sachsen
DRESDEN

CureALS: Stress granules and proteostasis in motor neurons: towards a mechanistic understanding of ALS (coordination)
Max Planck Institute of Molecular Cell Biology and Genetics
Forschungsgruppe Alberti

IRELAND

County Dublin
DUBLIN

Behavioral Changes in ALS: What Families and Health Care Professionals need to know
Trinity College Dublin
Research Motor Neurone - Trinity Biomedical Sciences Institute

ISRAEL

ISRAEL
TEL AVIV

Funded by an IRDiRC memberALS-degeneration: The molecular basis for neurodegeneration and muscle atrophy in ALS - IL
University of Tel-Aviv
Dept. of Physiology and Pharmacology

ITALY

LAZIO
ROMA

ITALY

LAZIO
ROMA

Proposal for an integrated approach to rare diseases: a study between basic laboratory models and clinical epidemiology in amyotrophic lateral sclerosis (ALS)
ISS - Istituto Superiore di Sanità
Reparto Farmaci per la Salute del Bambino e della Donna - Dipartimento del Farmaco

ITALY

LOMBARDIA
MILANO

Preclinical studies aimed to develop target genes based therapies for the treatment of amyotrophic lateral sclerosis
Istituto di Ricerche Farmacologiche "Mario Negri"
Laboratorio di Neurobiologia Molecolare

ITALY

LOMBARDIA
MILANO

Novel biomarkers of amyotrophic lateral sclerosis: role in pathogenesis and possible therapeutic targets
Istituto di Ricerche Farmacologiche "Mario Negri"
Laboratorio di Proteomica Traslazionale

ITALY

LOMBARDIA
MILANO

Novel biomarkers of amyotrophic lateral sclerosis: role in pathogenesis and possible therapeutic targets
Istituto di Ricerche Farmacologiche "Mario Negri"
Laboratorio di Proteomica Traslazionale

ITALY

LOMBARDIA
MILANO

Role of altered proteolysis in the degeneration of motor neurons in in vivo and in vitro models of Amyothrophic lateral sclerosis
Università degli Studi di Milano - Scienze Biomolecolari e Biotecnologiche
Dipartimento di Scienze Biomolecolari e Biotecnologie

ITALY

LOMBARDIA
PAVIA

Novel therapeutic strategies for Spinal Muscular Atrophy: testing the efficacy of cell-permeable peptides in preclinical models
Fondazione Salvatore Maugeri
Laboratorio di Ricerca sulle malattie Neurodegenerative

ITALY

PIEMONTE
TORINO

Funded by an IRDiRC memberMutations in the MATR3 gene as a cause of amyotrophic lateral sclerosis (ALS)
Ospedale Molinette
Centro regionale esperto per la sclerosi laterale amiotrofica

ITALY

PUGLIA
BARI

Amyotrophic lateral sclerosis (SLA) and riboflavin responsive multiple Acyl-CoA dehydrogenase deficiency (RR-MADD)
Università degli Studi di Bari Aldo Moro
Laboratorio di Biochimica e Biologia Molecolare E.Quagliarello

NETHERLANDS

Utrecht
UTRECHT

Funded by an IRDiRC memberEuro-MOTOR: European multidisciplinary ALS network identification to cure motor neuron degeneration (Terminated) - UK
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Neuromusculaire Ziekten

PORTUGAL

SUL
LISBOA

Respiratory Rehabilitation in Amyotrophic Lateral Sclerosis: clinical and biochemical impact.
Faculdade de Medicina da Universidade de Lisboa
Unidade de Neuromusculares

PORTUGAL

SUL
OEIRAS

Mechanisms of SOD1 toxic aggregation in neurodegenerative processes
Instituto de Tecnologia Química e Biológica
Protein Biochemistry Folding and Stability

SPAIN

Andalucía
SEVILLA

Funded by an IRDiRC memberClinical and pre-clinical investigation of neuromuscular diseases through computerized image analysis
IBIS - Instituto de Biomedicina de Sevilla
Programa de Neurociencias: Grupo de Mecanismos de Mantenimiento Neuronal

SPAIN

Aragón
ZARAGOZA

SPAIN

Cataluña
BARCELONA

Funded by an IRDiRC memberIdentification of diagnostic biomarkers for amyotrophic lateral esclerosis
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología

SPAIN

Cataluña
LLEIDA

Funded by an IRDiRC memberCell stress and mislocalization of transcription factors in ALS pathophysiology
Universitat de Lleida. Campus de Ciències de la Salut
Departamento de Medicina Experimental

SPAIN

Madrid
MADRID

Funded by an IRDiRC memberBiomarkers study in the pathological continuum between Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD)
Instituto de Investigación Hospital 12 de Octubre
Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares

SPAIN

Madrid
MADRID

Funded by an IRDiRC memberMultitarget chiral compounds for the treatment of neurodegenerative diseases: nicotinic ACh receptors ligands, Nrf2 inducers and antiinflammatory efect
Instituto de Investigación del Hospital de La Princesa
Área de neurotransmisión, neuroprotección farmacológica y enfermedades neurodegenerativas y neuropsiquiátricas

SWEDEN

Stockholms läns landsting
STOCKHOLM

In vitro molecular mechanism of amyotrophic lateral sclerosis
Stockholm University
Department of Biochemistry and Biophysics

SWEDEN

Västerbottens läns landsting
UMEÅ

SWEDEN

Västerbottens läns landsting
UMEÅ

Studies of misfolded SOD1 in amyotrophic lateral sclerosis (ALS)
Umeå University
Department of Medical Biosciences

SWEDEN

Västerbottens läns landsting
UMEÅ

Molecular portfolio of the extraocular muscles: clues to protection in muscular disease
University Hospital of Umeå
Department of Clinical Sciences

SWEDEN

Västerbottens läns landsting
UMEÅ

Genetic factors causing sporadic and familial amyotrophic lateral sclerosis (ALS/MND) with or without dementia
University Hospital of Umeå
Department of Pharmacology and Clinical Neuroscience

UNITED KINGDOM

Greater London
LONDON

Development of a diagnostic test for familial amyotrophic lateral sclerosis type 6 through mutation screening in FUS gene
National Hospital for Neurology and Neurosurgery
The Centre for Neuromuscular Disease

UNITED KINGDOM

Greater London
LONDON

Study the role of TDP43, a new gene mutation identified recently for amyotrophic lateral sclerosis in motor neurons
The National Hospital For Neurology and Neurosurgery
Department of Neurodegenerative Disease

UNITED KINGDOM

South Yorkshire
SHEFFIELD

MITOTARGET: mitochondrial dynamics in neurodegenerative diseases and assessment of the effects of new small molecules (WP1)
Sheffield Institute of Translational Neuroscience, University of Sheffield
Department of Neuroscience

UNITED KINGDOM

South Yorkshire
SHEFFIELD

UNITED STATES

Massachusetts
BOSTON

ITALY

VENETO
CONEGLIANO

Functional study of the Senataxin gene in Drosophila, responsible of motoneuron disease
IRCCS "E. Medea" - Polo Regionale di Conegliano
Associazione ''La Nostra Famiglia''

ITALY

VENETO
CONEGLIANO

Development of motoneuron disease models in Drosophila
IRCCS "E. Medea" - Polo Regionale di Conegliano
Associazione ''La Nostra Famiglia''

ITALY

VENETO
PADOVA

Modelling the role of Atlastin in physiology and moton neuron pathology
Università degli Studi di Padova
Dipartimento di Farmacologia

FRANCE

BOURGOGNE-FRANCHE-COMTE
STRASBOURG

Funded by an IRDiRC memberClinical and psychopathological approach of neuromuscular disease on gender identity
Université de Strasbourg
Subjectivité, lien social et modernité (EA3071)

FRANCE

ILE-DE-FRANCE
EVRY

FRANCE

ILE-DE-FRANCE
PARIS

Funded by an IRDiRC memberChildbirth and parenthood in women with motor disability related to rare diseases
Fondation hospitalière Sainte-Marie
Service d'Aide à la Parentalité des Personnes en Situation de Handicap

FRANCE

ILE-DE-FRANCE
PARIS

Funded by an IRDiRC memberHUMAn Neuromuscular Integrative System for drug discovery
Université Paris Descartes - Paris 5
Centre de Neurophysique, Physiologie et Pathologie - CNRS UMR 8119

UNITED KINGDOM

Greater London
LONDON

Explaining and changing adverse illness perceptions in muscle disease by a cognitive behavioural therapy technique
Guy's Hospital
Health Psychology Section, Psychology Department, Institute of Psychiatry

UNITED KINGDOM

Lothian
EDINBURGH

Genetic disorders of human brain development
Western General Hospital
MRC Human Genetics Unit

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

TREAT-NMD: Accelerating Treatments for Neuromuscular Diseases (coordination)
Newcastle upon Tyne Hospitals NHS Trust
Institute of Genetic Medicine

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

NMD-CHIP: societal aspects of the development of targeted DNA-chips for high throughput diagnosis of neuromuscular disorders (WP7)
PEALS Research Centre, Newcastle University, 4th Floor
Policy, Ethics and Life Sciences (PEALS) Research Centre

ITALY

CAMPANIA
NAPOLI

Funded by an IRDiRC memberTelethon Undiagnosed Disease Program - Revised Proposal
Azienda Ospedaliera Universitaria - Seconda Università degli Studi di Napoli
Laboratorio di Genetica Medica

Multicentric Research projects